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Abstract. Brucellosis is an important but neglected zoonosis that causes serious economic losses both in livestock and
human populations. The aim of the present study was to estimate the true prevalence of brucellosis together with diagnostic
sensitivity and specificity of three serological tests in humans of the northwestern part of Ecuador using a Bayesian approach
adjusted for the dependencies among the multiple tests to avoid any misinterpretation. In addition, the causal agent re-
sponsible for humanbrucellosiswasalso identified.Usinga total of 3,733samplescollected fromhumans in this areabetween
2006 and 2008, the prevalence of human brucellosis and the diagnostic test characteristics of the Rose Bengal fast agglu-
tination test (RBT), Wright’s slow agglutination test with ethylenediaminetetraacetic acid disodium salt dehydrate
(EDTA) (SAT-EDTA), and indirect ELISA (iELISA) were estimated using a Bayesian approach. The estimated true prevalence
of human brucellosis was 1% (credibility interval: 0.4–1.6). The sensitivities of iELISA and RBTwere higher than and similar
(95.1%and95.0%, respectively) to those of SAT-EDTA (60.8%). Even thoughall tests indicated a high specificity (> 99.0%),
thespecificityofSAT-EDTAwashighest (99.9%).Thecirculatingstrain in thisstudyareawas identified tobeBrucella abortus
biotype 4 based on culture andmicrobiological characterization. The RBT and the iELISA are recommended for estimating
the true prevalence of human brucellosis and/or for surveillance programs following their high sensitivities and specificities.
The proposed strategy supports evidence-based medicine for clinicians and policy-makers to ensure appropriate pre-
ventive and control program of brucellosis worldwide.
INTRODUCTION
Brucellosis is an infectious and contagious disease caused
by Gram-negative coccobacilli, which can survive in the cells
of the immune system. It has a high tendency to cause chronic
infections in multiple species including humans.1–3
In many countries, brucellosis is an important disease that
causes serious economic losses in livestock production.4 In
Ecuador, these losses are estimated at 5.5millionUS$per year.5
In humans, this zoonosis causes mainly losses in working time
and costs related to diagnosis and long treatment durations.6
Brucellosis is transmitted to man by direct contact with
blood, placentas, fetuses, or vaginal secretions of infected
animals and through consumption of products of animal origin,
mainly raw milk, cheese, or yoghurt. The disease may show
variable symptoms in humans with a tendency for recurrence,
even thoughmany times the infection is asymptomatic.7,8 The
incubation period varies between 1 and 5weeks, andBrucella
infectionmay be asymptomatic or symptomatic.9 The disease
can develop subclinically, acutely, or as a lasting condition
with variable progress.10
Despite the fact that brucellosis is a notifiable disease in
Ecuador until 2007, the true incidence of human cases re-
mains largely unknown because of underreporting. According
to the Ministry of Health (MSP), only 111 human cases were
reported between 1990 and 2007, whereas the National In-
stitute forStatistics andCensus (INEC) registered152persons
hospitalized because of brucellosis between 1995 and 2007,
in a country with 12 million inhabitants.11
Despite the lowsensitivity of culture, thedefinitivediagnosis
in humans consists in detecting the presence of the bacteria
by bacteriological examination. However, the high cost and
the risk for human infection during in vitro cultures prevent this
method from becoming the standard diagnostic tool. There-
fore, common immunological assays such as theRoseBengal
fast agglutination test (RBT), Wright’s slow agglutination test
with EDTA (SAT-EDTA), and indirect ELISA (iELISA) based on
the detection of antibodies against Brucella spp. have mostly
been used in combination for a practical early diagnosis of the
disease. Whereas the RBT detects the presence of IgM and
IgG1, the SAT-EDTA detects the presence of IgM and IgA and
the iELISA detects both IgG1 and IgG2.12,13 Because of the
fact, it is expected that tests are conditional dependent.13
Because each diagnostic assay has its characteristic sensi-
tivity and specificity, which varies according to its detectable
immunoglobulin isotype, the results of the multiple tests have
usually been assumed to follow amultinomial distribution and
aBayesian approach used to simultaneously estimate the true
prevalence and diagnostic sensitivity and specificity.14–16
An important con sideration in the evaluation of multiple
diagnostic tests is whether or not the tests can be assumed
conditionally independent of each other given the true disease
status. It has been demonstrated that the assumption of
conditional independence (CID) may lead to biased estimates
for test characteristics if in fact the tests are conditionally
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dependent.17 BecauseRBT, SAT-EDTA, and iELISAare basedon
sera (detection of and considered to be conditionally dependent
on each other), any estimation procedure should adjust for the
dependencies among the tests.14,15
There is a lackof reliable informationabout the trueprevalence
of human brucellosis in Ecuador at the population level. Indeed,
the aim of the present studywas to estimate the true prevalence
of human brucellosis together with diagnostic sensitivity and
specificity of RBT, SAT-EDTA, and iELISA applied to humans in
the northwestern part of Ecuador using a Bayesian approach. In
addition, we aimed to isolate and characterize Brucella re-
sponsible for human infections using culture-based methods.
METHODS
Ethical considerations. The protocol was thoroughly
reviewed and approved for ethics by the Bioethics Com-
mittee of the Biomedical Center, Central University of
Ecuador. Before being included in the study, all participants
provided informed written consent. For minors, parents/
guardians provided written consent on their behalf.
Description of the study and the study region. Between
2006 and 2008, a spatial cross-sectional surveywas conducted,
based on blood sampling of people from NW Ecuador together
with an epidemiological survey of brucellosis. The target pop-
ulation for this study was rural community along the provinces
selected and with a certain risk associated with animal man-
agement (Figure1). After informedconsent, a total of 3,733blood
samples were taken from persons inhabiting the high altitude or
SierraprovincessuchasCarchi (649samples), eastern Imbabura
(497 samples), and eastern Pichincha (1,386 samples) and the
coastal provinces such as Esmeraldas (195 samples), Manabı́
(377 samples), western Imbabura (535 samples), and western
Pichincha (94 samples). Selection of the zones was based on
their high prevalence of bovine brucellosis that is between 4.0%
and 10.62% in the Sierra and between 5.88%and 10.62% in the
Coast5 and the occurrence of 41.30% (19 of 46) of the human
cases,as reportedbyMSPbetween1997and2007,and51.97%
(79 of 152) of the hospitalized brucellosis patients, as reported
by INEC in 2008.11 A map of the zones at risk of brucellosis and
the study area is shown on Figure 1.
All the volunteer participants included in the studywere first
surveyed with a detailed questionnaire at the same time of the
blood culture sampling. This questionnaire was developed
attending technical and ethical consideration to register the
following information: personal identification (first name, family
name, address, contact details, and phone number if possible),
basic demographic data (age, gender, province of birth, and
province of residence), professional and/or occupational activities
and development period of such activity, contact with species of
livestock interest (cattle, sheep, pigs, goats, and horses), contact
with fetuses, aborted products, and/or secretions of animals of
livestock interest and eating habits (consumption of milk, cheese,
yogurt, livestock fresh blood and viscera, fetuses, and bovine
placenta). In addition, a section of the survey was designed to
collect information on the following symptoms detected by the
participant itself during the last 12 months before the date of the
bloodsampling: fever, shakingchills,weakness,night sweats, joint
FIGURE 1. Zones at risk of brucellosis in Ecuador and the location of the study area. Zones at risk of brucellosis in Ecuador: Zone 1, high
prevalence zone on Sierra; Zone 2, high prevalence zone in coastal area; Zone 3, low prevalence zone on Sierra; Zone 4, presumed low prevalence
zone in Amazonia; and Zone 5, presumed brucellosis-free zone of the Galapagos Islands. Location of the study area (provinces): A, Manabi; B,
Esmeraldas; C, Pinchincha; D, Imbabura; and E, Carchi. This figure appears in color at www.ajtmh.org.
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pains, muscles pains, headaches, allergies, insomnia, and an-
orexia. Data collected were then correlated with the serolog-
ical test results and were carefully analyzed, especially in
those cases of participants with at least one of the tests
showing positive results (n = 104).
Diagnostic assays. Three serological assays to detect
antibodies against Brucella spp. were used: RBT, SAT-EDTA,
and iELISA.18 The protocols are available in Supplemental
Appendix A. Samples were processed and analyzed in the
laboratory for immunodiagnosis at the International Centre for
Zoonoses (CIZ) of the Central University of Ecuador.
Isolation and typing of Brucella spp. Isolation of the causal
agentwas reachedbybloodculture using theautomatedsystem
BACTEC (Becton Dickinson Diagnostic Instrument Systems,
Sparks, MD) facilitated by the Microbiology laboratory of the
“Hospital Vozandes.”Notall the sampledpopulation in this study
was submitted to blood culture process. Thus, selection of acute
cases to make the most of the possibilities of getting the causal
agent isolated was carried out after careful analysis of the sero-
logical assay results previously performed. As follows, a number
of participants (n = 22) showing positive results for RBT and
elevated titers of SAT-EDTA were contacted and sampled for a
blood culture tests on their location. For logistical reasons con-
cerning the suitable and almost immediate transportation of
bloodculture samplesuntil the “Hospital Vozandes” inQuitocity,
only participants located in the highlandswere selected. None of
them was a minor (< 18 years old) at the moment of sampling.
For each participant, a set of three bottles were sampled for
blood culture testing following internal procedures stated at
CIZ. Briefly, the set consisting of threebottleswas obtainedby
three different punctures separated by 30 minutes each. Ten
milliliters of venous blood was taken using a syringe from the
cephalic vein and then inoculated into the blood culture bottle
after changing a new sterile needle. The bottles were then
maintained into a plastic thermic box at room temperature
(18–25C) and then transported as fast as was possible to
the “Hospital Vozandes” laboratory.
Each bottle was incubated into the BACTEC system until
positivebacterial growthwasdetectedor for amaximumperiod
of 30days tobeconsideredasnegative. Isolateswere identified
as Brucella sp. following the internal procedures stated in the
hospital. Then, the species andbiotypewere determinedbased
on the followingassaysperformedatCIZandtheVeterinaryand
Agrochemical Research Centre: 1) macroscopic and micro-
scopic observation of the colonies in purified culture plates, 2)
biochemical assays (oxydase, catalase, and urease), 3) pro-
ductionofH2S,4)CO2growth requirement,5) growth instained
media (thionine, basic fuchsin, and safranin), 6) agglutination
with monospecific sera A and M, and 7) performance of poly-
merase chain reaction (PCR)—bscp31 (i) gene and PCR-
Abortus, Melitensis, Ovis and Suis (AMOS) (ii). The two PCRs
werechosen from theamplified regionsof twodifferentBrucella
genes: 1) primers B4 (5P-TGG CTC GGT TGC CAA TAT CAA-
3P) and B5 (5P-CGC GCT TGC CTT TCA GGT CTG-3P) am-
plified a 223-bp fragment present on a gene encoding a 31-kDa
Brucella abortus antigen19,20 2) a 498-bp fragment was ampli-
fied with AMOS PCR, which was derived from IS711 gene.21
Statistical analysis. Apparent prevalence and correlation
analysis. The apparent prevalencewas calculated for the three
separate tests and for the combined tests using a parallel in-
terpretation, that is, a person is considered positive if one
or more tests yielded a positive result. The concordance
observedwas computedbetween the results of the respective
tests, and they were plotted. This concordance observed was
obtained counting the concordance between positive and
negative in two tests with respect to the total samples.
Model building and diagnostics. Using the cross-classified
test results for the three tests, it was assumed that the resulting
cell frequencies/counts followed a multinomial distribution.
Using themodelsdevelopedbyBranscumet al.15 andBerkvens
et al.,16 the corresponding multinomial cell frequencies were
expressed in terms of the true prevalence of human brucellosis
in the population, the sensitivities, and the specificities of RBT,
SAT-EDTA, and iELISA and additional terms to account for the
conditional dependence (CD) between each pair of tests
(Supplemental Appendix B). In this scenario, including all pa-
rameters and possible interactions between the three individual
tests requires 15 parameters to be estimated, namely, the
prevalence, the sensitivity, and the specificity of the first test;
two conditional sensitivities and two conditional specificities for
thesecond test; andfinally, fourconditional sensitivitiesand four
conditional specificities for the third test. This model is in fact
non-identifiable because the data only allow seven parameters
to be estimated. As none of the three tests is considered a gold
standard test and the tests are not conditionally independent,
constraints have to be imposed on a subset of the parameters
to reduce the number of parameters to be estimated.16
By combining the results of the applied assays (RBT, SAT-
EDTA, and iELISA), the prevalence of this zoonosis among
humans in the NW Ecuador was estimated together with the
sensitivity and the specificity of each of the tests. To evaluate
the goodness of fit of the models, the Bayesian P-value, de-
viance information criterion (DIC),22 and the number of effec-
tive parameters estimated (pD)16 were used as calibrating
parameters. Briefly, the DIC ensures that the most parsimo-
niousmodel is used. It is calculated asDIC=pD+D, withD the
mean posterior deviance and pD the number of parameters
effectively estimated by the model. Models with a smaller DIC
should be preferred over models with a larger DIC. The
Bayesian P-value is a posterior predictive check that detects
lack of fit of themodel to the data. It is based on the difference
between the deviance of the observations and the deviance of
observations generated randomly from the presently fitted
model and should have a value around 0.50. The values of pD
and DIC evaluated based on the posterior means of the mul-
tinomial probabilities and those based on the posterior means
of the parameters should be as close as possible.16
Modeling CD. Using the model that assumes CID among
the three tests, given the true disease status of individuals as
the baseline model, CD (i.e., PðT +2 \T +1 jD+ÞPðT +2 \T1 jD+Þ,
PðT2 \T1 jDÞPðT2 \T +1 jDÞ, where T1 or T2 are the positive
or negative results for test 1 or test 2 and D is the individual
disease status [+] or [−]) between each pair of tests was esti-
mated using different parameterizations of the model that
assumed CD between tests.15,16,23 Essentially, in the first
parameterization, the CD between iELISA and RBT was
modeled and the data used were based on cross-classified
test results with iELISA on the first column, RBTon the second
column, and SAT-EDTA on the third column (Table 1).
The remaining two parameterizations involving the CD
between two tests were obtained by switching columns
for iELISA with RBT and SAT-EDTA in turn. In addition,
three models were constructed with CD between the pairs:
iELISA/RBT and iELISA/SAT-EDTA, iELISA/RBT and
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RBT/SAT-EDTA, and between iELISA/SAT-EDTA and
RBT/SAT-EDTA, respectively.23 Finally, a model with CD
among all the three tests was considered (all pairs in-
clusive) separately among infected and noninfected in-
dividuals and combined.
The models can be summarized as follows:
• Model 1: CID
• Model 2: CD between RBT and SAT-EDTA
• Model 3: CD between iELISA and RBT
• Model 4: CD between iELISA and SAT-EDTA
• Model 5: CD between iELISA and SAT-EDTA and between
RBT and SAT-EDTA
• Model 6: CDbetween iELISA andRBT and between iELISA
and SAT-EDTA
• Model 7: CD between iELISA and SAT-EDTA and between
RBT and SAT-EDTA
• Model 8: CD among all tests for infected subjects that are
between iELISA andSAT-EDTA, between iELISA andRBT,
and between RBT and SAT-EDTA
• Model 9: CD among all tests for noninfected subjects that
are between iELISA and SAT-EDTA, between iELISA and
RBT, and between RBT and SAT-EDTA
• Model 10: CD among all tests that are between iELISA and
SAT-EDTA, between iELISA and RBT, and between RBT
and SAT-EDTA
Representing theCDbetween pairs of tests among infected
humans by a and among the noninfected population by b,
posterior estimates were obtained along with their 95%
credibility intervals (Cr. Is.). If the Cr. I. includes zero, it will
imply that the data do not provide enough evidence against
the null hypothesis of CID, whereas if the interval excludes
zero, the CID assumption between the two tests will be
rejected in favor of the alternative hypothesis ofCD.Allmodels
were compared using the DIC. To be considered significantly
different, the reduction inDICbetween any twomodels should
be more than three units. In situations where the difference in
DICwas smaller than three units, themodelswere assumed to
be similar and selection was based on parsimony.22
Prior distributions for parameters. In Ecuador, the prev-
alence, sensitivities, and specificities of the three tests used
are not known. Priors were therefore introduced based on
similar studies among humans in different countries found in
the literature. The average prevalence of brucellosis among
humans ranged between 0 and 0.2,24,25 and sensitivity and
specificity ranged between 0.88 and 1 and between 0.93 and
1, respectively, for iELISA; 0.49 and 1 and between 0.97 and 1
forSAT-EDTA, respectively; and last, 0.9 and1and0.95and1,
respectively, forRBT.2,26–28Lowerandupper limitsof these ranges
were used to define uniform distributions for the parameters.
Prior information on the eight covariance parameters (four
for infected and four for the noninfected individuals) were not
available, so their ranges were generated based on priors for
the sensitivities and specificities for the three tests (see
Supplemental Appendix B). Uniform prior distributions were
then assumed based on the ranges.15
Model diagnostics.All models were run using three chains, a
burn-in period of 10,000 iterations, and another 20,000 iterations
(with thinning applied) to obtain the posterior estimates. Trace
plots were simultaneously combined with autocorrelation plots
to explore the convergence of the model. A more formal test for
convergence, the Brooks, Gelman, and Rubin (BGR) conver-
gencestatisticwasused toassessmodel convergence, andonly
properly converged models were further considered.29 The
WinBugs code used is found in Supplemental Appendix B.
Sensitivity analyses. Several studies have indicated that
for theCDmodel, the prior information influences theposterior
estimates.15,30,31 The influence of prior information on the
posterior estimates was assessed by conducting a sensitivity
analysis. This was performed by using non-informative priors
(NIPs) and slight perturbations (in steps of 10% or 15%) of the
prior intervals.30 The following sets of priors were considered:
• NIP for the prevalence and information priors (IPs) for the
sensitivities and specificities
• NIP for the prevalence and for the sensitivities and IPs for
the specificities
• NIP for the prevalence and for the specificities and IPs for
the sensitivities
• IP for the prevalence and NIPs for the sensitivities and
specificities
• IP for the prevalence and for the sensitivities and NIPs for
the specificities
• IP for the prevalence and for the specificities and NIPs for
the sensitivities
• Perturbations of the prior interval
For each set of alternative prior distributions considered for
the parameters, the model was run with the same number of
chains and similar diagnostics were performed. It is also
known that inferences based on multinomial data with zero
cell frequencies may lead to slow convergence or non-
convergence, and hence lead to inaccurate results, espe-
cially when the total sample size is small.32 Because there are
no immediate corrections or exact methods, the effects of
zero-multinomial frequencieson theestimateswere evaluated
by replacing each zero frequency with a one. Replacing zero
frequencies byoneshas aminimumeffect on thebalanceprior
information versus observed data, but helps convergence,
and hence assists to evaluatemodel consistency/robustness.
RESULTS
Apparent prevalence and correlation analysis. The
cross-classified test results of the three serological tests on
the 3,733 samples are shown on Table 1. The apparent
prevalence was 0.56% (95% CI: 0.35–0.85) based on SAT-
EDTA, 1.63% (95% CI: 1.25–2.09) based on RBT, and 1.55%
(95% CI: 1.18–2.00) based on iELISA. The prevalence of
TABLE 1
Cross-classified test results for human brucellosis in cattle in the
northwestern part of Ecuador based on RBT, SAT-EDTA, and
iELISA
RBT SAT-EDTA iELISA Number
0 0 0 3,663
0 0 1 7
0 1 0 0
0 1 1 2
1 0 0 11
1 0 1 31
1 1 0 1
1 1 1 18
Total – – 3,733
iELISA = indirect ELISA; RBT = Rose Bengal test; SAT-EDTA =Wright’s slow agglutination
test with EDTA; 1 = positive; 0 = negative.
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brucellosis based on the three tests was 1.88% (1.46–2.36),
following a parallel interpretation. The prevalence based on
RBT was observed to be similar to that obtained based on
iELISA. A correlation analysis yielded a high observed con-
cordance of 0.96 between the results obtained based on RBT
(Test 1) and iELISA (Test 3). In addition, between RBT (Test 1)
and SAT-EDTA (Test 2) and between SAT-EDTA (Test 2) and
iELISA (Test 3), the observed concordances also appeared to
be high (0.97 and 0.96, respectively).
Model selection. The estimated DIC, pD, and Bayesian
P-values for the different models are presented in Table 2.
A remarkable observation from themodelswas the closenessof
the Bayesian P-values to 0.5 (values ranged between 0.4817
and 0.5636), indicating that all the models we tested provided
acceptable fit to the data. All the DIC values were fairly close to
each other with differences smaller than three. Using the CID
model as the baseline model (DIC = 34.230), the only other
model that yielded a slightly higher reduction in DIC than the
baseline model wasModel 9 (DIC = 31.955); the model with CD
among the three tests for noninfected subjects (Table 2). Be-
cause of the borderline significance of the difference in DIC
(difference = 2.3), the selection of the most appropriate model
was based on parsimony and completeness (the fewer the
number, the better the estimated parameters). Model 9
appeared to be more parsimonious because its pD, 4.376, is
slightly lower than that of model 10 (pD = 4.597) (Table 3). The
final model was therefore based on the model with CD among
the three tests for noninfected individuals (Model 9).
For this model, an observation of the trace plots indicated
that the chains were mixing properly. However, the autocor-
relation plots indicated that there were significant autocorre-
lations up until lag 40. On thinningwith a thinning coefficient of
60, we ensured that the samples were independent. The BGR
plots indicatednoproblemswith convergence. In addition, the
estimated Bayesian P-value for the final model was 0.4865
further corroborating the aforementioned findings that the
model provides a good fit to the data. The estimated pD and
DIC were 4.376 and 31.955, respectively. These values in turn
appear to be reasonably close to theoptimal values (5.505 and
35.972, respectively) further supporting the claim that the
model fits the data well.
True prevalence, accuracy, and CD. The posterior mean
estimates of the prevalence, the sensitivity, the specificity,
and the dependency coefficients for the three tests among
noninfected subjects are shown in Table 3. According to the
results, the true prevalence of brucellosis among humans
was 1.0% (95% Cr. I.: 0.40–1.60). The performances of
iELISA and RBT were very similar with estimated sensitivities
and specificities of 95.1% (88.7–99.8) and 95.0% (90.3–99.7)
and 99.3% (98.7–99.8) and 99.2% (98.6–99.7), respectively.
Wright’s slow agglutination test with EDTA had the lowest
sensitivity of 60.8% (40.7–96.6) and the highest specificity of
99.9% (99.8–1).
The 95% probability intervals for the conditional depen-
dency coefficients among the three tests for the noninfected
humans excluded zero, implying that the hypothesis of CID
among the three tests is rejected in favor of the alternative
hypothesis of CD. The highest CD coefficient was observed
between the specificities of iELISA and RBT (0.005), whereas
a lower CD was observed between iELISA and SAT-EDTA
and between SAT-EDTA and RBT (0.0004) (Table 3).
Sensitivity analysis. When a NIP was used for the preva-
lence and IPs used for the sensitivities and specificities, or IPs
used for the specificities and NIPs used for the sensitivities,
the results were quite similar. On the other hand, when NIPs
were used for theprevalence and the sensitivities and IPswere
used for the specificities, there were slight but nonsignificant
differences in the estimated prevalence and specificities.
Similarly, when using an IP for the prevalence and NIPs for the
sensitivities and specificities, or IPs used for the specificities
and NIPs were used for the sensitivities, there were slight but
nonsignificant differences (Cr. Is. overlap) in the estimated
prevalence and sensitivities. The results were quite similar
when IPswas used for the prevalence and the sensitivities and
NIPs were used for the specificities.
Decreasing the lower limits of all the prior intervals by 10%
had no influence on the estimated parameter values and their
95% Cr. I. However, when both the lower and upper limits of
the prior interval were decreased by 10%, the model did not
converge (pD = 2.57 and DIC = 688.54). In addition, the
Bayesian P-value was 1, indicating a considerable lack of
fit of the data to the model.
TABLE 2
Deviance information criterion (DIC), number of estimated parameters (pD), and Bayesian P-values for the model assuming conditional in-
dependence (CID), models assuming condition dependence between each of two tests, models including pairs of conditional dependence (CD),
and a model with condition dependence between all the three tests
Type of model DIC pD Bayesian P-value
Model 1: CID model 34.230 3.822 0.5357
Model 2: CD between RBT and SAT-EDTA among all subjects 34.666 4.359 0.5354
Model 3: CD between iELISA and RBT among all subjects 34.610 4.888 0.4887
Model 4: CD between iELISA and SAT-EDTA among all subjects 34.472 4.259 0.5357
Model 5: CD: between iELISA and RBT and between SAT-EDTA and RBT
among all subjects
34.480 4.513 0.5021
Model 6: CD: between iELISA and RBT and between iELISA and SAT-EDTA
among all subjects
34.437 4.690 0.4817
Model 7: CD: between iELISAandSAT-EDTAandbetweenRBTandSAT-EDTA
among all subjects
32.664 4.226 0.5636
Model 8: CD: between iELISAandSAT-EDTAandbetweenRBTandSAT-EDTA
among infected subjects
35.563 4.525 0.5515
Model 9: CD: between iELISAandSAT-EDTAandbetweenRBTandSAT-EDTA
among noninfected subjects
31.955 4.376 0.4865
Model 10: CD: between iELISA, SAT-EDTA and between iELISA and RBT and
between RBT and SAT-EDTA among all subjects
32.007 4.597 0.5059
iELISA = indirect ELISA; RBT = Rose Bengal test; SAT-EDTA =Wright’s slow agglutination test with EDTA; bold values indicate the DIC, pD and Bayesian P-value corresponding to the bet model.
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Finally, replacing the zero-observed frequencies with one
and running all the different models, none of the models
appeared to be doing better than theCIDmodel. However, the
model with CD between the specificities yielded a DIC that
was closest to that of the CID model (data not shown). Based
on this model, the estimated prevalence, sensitivities, speci-
ficities, and dependence coefficients were quite similar (Cr. Is.
overlap, data not shown).
IsolationandcharacterizationofcirculatingBrucellaspp.
in Northwest Ecuador. From three positive cases (of 22
tested), B. abortus biotype 4 was isolated. Blood cultures were
only positive for patients with higher levels of IgM antibodies
(SAT-EDTA). Detailed information about these three persons
with positive blood cultures (as well as the culture-negative
persons) is given in Table 4 with the characteristics of the iso-
lations, bacteriological data, and PCR in Table 5 and Figures 2
and 3, respectively. In Figure 2, the gel of agarose for electro-
phoresis shows the amplification of the bscp31 gene; LaneMP
(molecular weight marker): 100 bp DNA Ladder and Lane
H1–H3 of human strains. In Figure 3, the 498-bp fragment was
amplifiedwithAMOSPCR,whichwasderived from IS711gene.
The results of the retrospective questionnaire, administered
to the seropositive persons relating to possible symptoms (in
the last year) relevant for brucellosis, are presented in Table 6.
DISCUSSION
Given that the main objective of an epidemiological survey
on human brucellosis should include the identification of
brucellosis cases together with the determination of the
source of infection that is occupational or alimentary,33
the present study aimed to provide a reliable estimate of the
prevalence based on the detection of antibodies against
Brucella spp., and the isolation and identification of the causal
agent among humans in the NW Ecuador.
The estimation of the true prevalence and diagnostic test
characteristics was performed using a Bayesian approach
in the absence of a standard reference test and with no
TABLE 3
Posterior mean estimates and 95% credibility intervals (Cr. I.) of the prevalence, sensitivities (Se), and specificities (Sp) of iELISA, SAT-EDTA, and
RBT and conditional dependence (CD) coefficients between the three tests among noninfected subjects
Test Parameter Prior
Model 1 Model 9
Posterior mean (Cr. I.) Posterior mean (Cr. I.)
RBT Se Uniform (0.90–1) 0.936 (0.902–0.981) 0.950 (0.903–0.997)
Sp Uniform (0.95–1) 0.997 (0.995–0.999) 0.992 (0.986–0.997)
SAT-EDTA Se Uniform (0.40–1) 0.446 (0.402–0.537) 0.608 (0.407–0.966)
Sp Uniform (0.99–1) 0.999 (0.999 –1.000) 0.999 (0.998–1)
iELISA Se Uniform (0.88–1) 0.942 (0.885–0.991) 0.951 (0.887–0.998)
Sp Uniform (0.93–1) 0.998 (0.998–0.999) 0.993 (0.987–0.998)
Prevalence Uniform (0–1) 0.015 (0.011–0.020) 0.010 (0.004–0.016)
iELISA and SAT-EDTA CD – – 0.0004 (0.00001–0.00156)
iELISA and RBT CD – – 0.0046 (0.00022–0.00956)
RBT and SAT-EDTA CD – – 0.0004 (0.00001–0.00147)
DIC – 34.230 31.916
pD – 3.822 4.372
Bayesp – 0.5357 0.4817
Bayesp = Bayesian P-values; DIC = Deviance information criterion; iELISA = indirect ELISA; pD = number of estimated parameters; RBT = Rose Bengal test; SAT-EDTA = Wright’s slow
agglutination test with EDTA.
TABLE 4
Results of bloodcultures frompatientswith high serological titers concomitantwith brucellosis presumptive clinical symptoms (northwest Ecuador)
N ID Sample code Age Gender Occupation RB SAT-EDTA (UI/mL) iELISA (U/mL) Blood culture
1 93 SHB-Ma-93 28 M Farmer + − 60 −
2 104 SHB-Ma-104 22 M Farmer + 100 60 −
3 146 SHB-Ma-146 17 M Student + 80 60 −
4 187 SHB-Ma-187 49 F Farmer − 80 − −
5 198 SHB-Ma-198 28 M Farmer − − 30 −
6 325 SHB-Ma-325 49 F Farmer + 100 60 −
7 344 SHB-Ma-344 50 M Farmer − 50 − −
8 372 SHB-Ma-372 39 M Farmer + 100 60 −
9 820 SHB-IA-1 41 M Veterinary lecturer + 80 60 −
10 821 SHB-IA-2 26 M Farmer + 100 60 −
11 822 SHB-IA-3 39 M Farmer + 100 60 −
12 825 SHB-IA-6 41 M Farmer − 100 60 −
13 2,202 SHB-Cam-Nor-5 39 F Slaughterhouse worker + 50 60 −
14 2,330 SHB-Cam-Nor-133 42 M Slaughterhouse worker + 40 60 −
15 2,331 SHB-Cam-Nor-134 55 M Transporter + − 50 −
16 2,343 SHB-Cam-Nor-146 50 F Slaughterhouse worker + − 48.6 −
17 2,348 SHB-Cam-Nor-151 66 F Slaughterhouse worker + 60 60 −
18 2,349 SHB-Cam-Nor-152 36 F Slaughterhouse worker + 320 14.4 +
19 2,353 SHB-Cam-Nor-156 35 M Slaughterhouse worker + 100 26.2 −
20 2,356 SHB-Ay-10 27 M Veterinary student + 1,600 60 +
21 3,144 SHB-Zon-Nor-370 58 M Farmer + 800 60 +
22 3,409 SHB-Zon-Nor-635 21 M Farmer + 960 60 −
ID = identification number; iELISA = indirect ELISA; RBT = Rose Bengal test; SAT-EDTA = Wright’s slow agglutination test with EDTA.
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knowledge about the true disease status of individuals. The
method allowed for the incorporation of prior knowledge about
prevalence of human brucellosis, test sensitivities, and speci-
ficities based on previous studies or expert opinions and the
estimation of the dependence between the three tests condi-
tional on the true disease status. Different models were con-
structed based on different combinations of the dependencies
between the tests. Using appropriate model diagnostic tools
such as the DIC, pD, and Bayesian P-values, it was demon-
strated that the models incorporating the different covariance
structures did not perform significantly better that the CID
model. However, the model with CD among noninfected indi-
vidualswas chosen for completeness. In addition, as explained
in the introduction, the CD between tests is the most plausible
biological hypothesis taking into account the immunological
effectors that are implicated in each test.12,13
The preference for the model 9 (CD for noninfected cases) is
related to the appraisal of several quality criteria (pD, DIC, and
Bayes-p), but there appears to be no explicit biological expla-
nation for this preference and its implications. It indicates that if
the three tests in question (i-ELISA, SAT-EDTA, and RB) are
applied to a noninfectedpersonand if a first test is negative, the
twoother test(s) also tend to remainnegative.Equivalently, if the
first test ispositive (i.e., a false-positiveserological reaction), the
other tests also have a tendency to bepositive. This findingwas
previously demonstrated for other species.12 Conversely, in an
infected person, if one test result is positive, the results for the
other tests are not necessarily positive because the stage of
infectionof thepatientbecomes important (early infectionmostly
with presence of IgM versus later infectionmostly with presence
of IgG). Implications formedicalpersonnel include the importance
of a proper anamnesis and the use of amulti-testing for a correct
interpretation of the serological results in brucellosis-suspected
patients.
In the present study, an overall seroprevalence of 1.88% (CI:
1.48–2.38) (70 in 3,733) was found in the entire study region,
which is in sharp contrastwith the official data of the Ecuadorian
MSP that is only 67 cases between 2003 and 2007 (on a pop-
ulation of 12 million). The true prevalence was however esti-
mated to be 1% (Cr. I.: 0.4–1.6).11 The results of the present
investigation, of previous studies and the observations de-
scribed by Ron-Roman et al.,34 indicate a serious under-
reporting of human brucellosis in Ecuador and a rather high
seroprevalence of this zoonosis in the rural population involved
in animal production. In several American countries, human
brucellosis doesnot seemtobevery important, yet the reported
figures may not reflect the real situation. The difficulties related
to the diagnosis and the often ambiguous or even absent clin-
ical symptoms are probably the principal reasons for the sub-
notification.33,35 The highly variable clinical reactions due to
brucellosis, contributing to the difficulties in recognizing the
disease,8,3 were also noted in the present study and underline
the need for reliable diagnostic tests.1
The high concordance observed between the results of the
three different tests (³ 0.96) is probably because the same
effectors (IgG1 and/or IgM) are detected by several tests.
Therefore, it is expected that tests are biologically conditional
dependent.12,13
The use of the Bayesian approach is incomplete without an
assessment of variations in the prior information and the data
TABLE 5










Growth on colorants Agglutination with serum
Thionine 20 μg Thionine 10 μg Basic fuchsin 20 μg Safranin 100 μg A M
SHB-Cam-Nor-152 Ec-CIZ-Hum1 + + + − – + + – +
SHB-Ay-10 Ec-CIZ-Hum2 + + + – – – – – +
SHB-Zon-Nor-370 Ec-CIZ-Hum3 + + + + – + + – +
B2† + + + – – – – + –
B9‡ + – + + + + + – +
CIZ = International Centre for Zoonoses.
* Blood culture.
† Control Brucella abortus biotype 2.
‡ Control B. abortus biotype 9.
FIGURE 2. PCR—bscp31 of Brucella from blood cultures, isolated from positive persons. B2 = control Brucella abortus biotype 2; CB = Blank
control; CIZ = International Centre for Zoonoses; H1 = Human sample 1 (Ec-CIZ-Hum-1); H2 = Human sample 2 (Ec-CIZ-Hum-2); MP = Molecular
weight marker (100 bp AND Ladder 0.5 μg/lane 2% agarose gel stained). *Samples from complementary studies at CIZ.
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on the estimated parameters using a sensitivity analysis.30,32,36
Sensitivity analyses indicated that the use of non-informative
or lowly informative priors had no significant influence on the
estimated prevalence and test sensitivities and specificities. It
was also found that replacing the zero frequencies with one’s
yielded estimates that were similar to those based on the
original data. This in turn suggests that the results of our study
were dominated by the data as compared with the prior in-
formation, and thus are reliable.
The causal agent, that is, B. abortus biotype 4, was isolated
and characterized in (apparently healthy) patients with high
levels of IgM antibodies. Biotyping Brucella is important for
the epidemiological knowledge because it can reveal geo-
graphical characteristics and allow a better understanding of
the spread of the disease.37 Unfortunately, isolating and typ-
ing of Brucella spp. is not always possible because it requires
high biosecurity laboratories and trained personnel. Further-
more, the low number of successful isolations in the present
study is partly because of the localization of the bacteria in
specific tissues and organs such as the bone marrow, cere-
brospinal fluid (CSF), liver, kidneys, and spleen, which renders
isolation from blood very unlikely.9,30
In the present study, 24.29% of the persons with a positive
seroreaction showed no symptoms at all (Table 6). This is
lower than the 45.6% reported by Perez et al.38 and the 99%
found in a retrospective study of the symptomatology by
Hernández-Bastida et al.39 This absence of typical symptoms
is obviously one of the reasons for underreporting and the
lack of data about the disease.3
The absence of a National Policy and differential diagnostic
tests hinders the development of surveillance and control pro-
grams in high-risk areas. It is thus difficult to have a realistic idea
about incidence of the disease. In the past, little attention was
given to brucellosis in Ecuador and it is necessary to develop
programs to control (and eventually eradicate) brucellosis in
the identified risk areas whereby highly sensitive diagnostic
methods will be used both for humans and for animals with
the objective of obtaining an early warning system and to
determine the correct prevalence at national level.
Ecuador cannot be considered an endemic country for
human brucellosis based on reported data40,41 although the
results of the present study, basedon factual data, prove quite
the opposite. Underreporting and the absence of an active
epidemiological vigilance may be the main reason for un-
derestimation in supposedly brucellosis-free regions.
Finally, it is of utmost importance that evidence-based
information be given to national and international donor
organizations involved with future prevention, control, and
research programs on brucellosis.
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TABLE 6
Human brucellosis: symptoms and frequency within the seropositive
group (n = 70)
Symptoms Positive cases Percentage
Muscular pain 29 41.43




Nocturnal sweating 13 18.57
Cardiac problems 10 14.29
Anorexia 4 5.71
Insomnia 4 5.71
No symptoms 17 24.29
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Belgium, E-mail: claude.saegerman@uliege.be.
Reprint requests: Jorge Ron-Román, International Center for Zoono-
ses, Central University of Ecuador, P.O. Box 17-03-100, Quito,
Ecuador, E-mail: jwron@espe.edu.ec, Fax: +59322904801.
REFERENCES
1. Young EJ, 1997. Especies de brucella. Mandell G, Bennett J, Dolin
R, eds.Enfermedades Infecciosas, Principios y Practica. Buenos
Aires, Argentina: Editorial Medica Paramericana SA, 2300–2320.
2. Orduña A et al., 2000. Evaluation of an immunocapture-
agglutination test (Brucellacapt) for serodiagnosis of human
brucellosis. J Clin Microbiol 38: 4000–4005.
3. SaegermanC,BerkvensD,GodfroidJ,WalravensK, 2010.Bovine
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